LPA-CGR avocats, Eversheds, FieldFisher, Mc Dermott Will & Emery and Jones Day advised on the deal
A consortium of investors made up of Sagard NewGen, Socadif Capital Investissement, IDIA Capital Investissement and MACSF has reached an agreement with the management of Laboratoires DELBERT, which specialises in the acquisition and remarketing of medicines of major therapeutic interest (the “MMTIs”), particularly in infectiology, oncology and psychiatry, to take a minority stake and provide equity capital.
This contribution of €20m of equity is supplemented by unit-branch financing provided by BPIFrance and CIC Mezzanine, also for €20m, which will give the French laboratory, leader in its sector, the means to accelerate the pace of acquisition of new marketing authorisations as well as its internationalisation.
This fund raising was conducted simultaneously with the acquisition of Lepticur (a major anti-Parkinsonian drug) from SANOFI-AVENTIS.
LPA-CGR avocats advised Laboratoires DELBERT in the context of the entry of the consortium into its capital and the unit-branch financing, with a team led by Mathieu Selva-Roudon, partner and Noémie Attar, associate, on the tax aspects, as well as Raphaël Chantelot, partner, Thibault Willaume, counsel and Yvan Vérité, associate, on the corporate aspects.
Mc Dermott Will & Emery advised Sagard with Diana Hund and Maxime Fradet
FieldFisher advised Socadif and IDIA with Pascal Squercioni and Daniel Da Cruz Rodrigues.
Eversheds advised BPIFrance with Sophie Perus and Sébastien Pontillo.
LPA-CGR avocats advised Laboratoires Delbert with Raphaël Chantelot (M&A) and Mathieu Selva-Roudon (Tax)
SANOFI was advised by Jones Day – Gaël Saint-Olive.
Involved fees earner: Sophie Perus – Eversheds Sutherland; Sébastien Pontillo – Eversheds Sutherland; Daniel Da Cruz Rodrigues – Fieldfisher; Pascal Squercioni – Fieldfisher; Gaël Saint Olive – Jones Day; Raphael Chantelot – LPA-CGR avocats; Mathieu Selva-Roudon – LPA-CGR avocats; Maxime Fradet – McDermott Will & Emery; Diana Hund – McDermott Will & Emery;